{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["153(8)"],"submitter":["Hundertmark MJ"],"pubmed_abstract":["Background
We report IMPROVE-DiCE (Improve Diabetic Cardiac Energetics), a 2-part open-label, phase 2a trial evaluating the safety and effectiveness of ninerafaxstat, a novel therapeutic designed to enhance cardiac energetics. Between May and September 2021, part 1 enrolled patients with type 2 diabetes and obesity without heart failure with preserved ejection fraction (HFpEF). Between January 2023 and June 2024, part 2 enrolled patients with type 2 diabetes, obesity, and HFpEF.Methods
Forty-two participants received 200 mg ninerafaxstat twice daily (part 1, n=21, 43% women, 72±0.5 years of age, 4-8 weeks; part 2, n=21, 29% women, 71±6 years of age, 12 weeks). Myocardial energetics (phosphocreatine-to-ATP ratio [PCr/ATP], primary outcome) and function (rest and dobutamine s"],"journal":["Circulation"],"pagination":["550-563"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12928817"],"repository":["biostudies-literature"],"pubmed_title":["IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes."],"pmcid":["PMC12928817"],"pubmed_authors":["Hundertmark MJ","Rao P","Henry JA","Gerszten RE","Dehbi HM","Yavari A","Birkhoelzer SM","Shi X","Chamberlin P","Tyler DJ","Sarwar R","Rider OJ","Lewis AJ","Valkovic L","Frenneaux MP","Matthews V","Mozes F","Miller JJJJ","Patel J","Robbins JM","Portwood C","Zheng S","Grist J","Neubauer S","Siu AG"],"additional_accession":[]},"is_claimable":false,"name":"IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes.","description":"Background
We report IMPROVE-DiCE (Improve Diabetic Cardiac Energetics), a 2-part open-label, phase 2a trial evaluating the safety and effectiveness of ninerafaxstat, a novel therapeutic designed to enhance cardiac energetics. Between May and September 2021, part 1 enrolled patients with type 2 diabetes and obesity without heart failure with preserved ejection fraction (HFpEF). Between January 2023 and June 2024, part 2 enrolled patients with type 2 diabetes, obesity, and HFpEF.Methods
Forty-two participants received 200 mg ninerafaxstat twice daily (part 1, n=21, 43% women, 72±0.5 years of age, 4-8 weeks; part 2, n=21, 29% women, 71±6 years of age, 12 weeks). Myocardial energetics (phosphocreatine-to-ATP ratio [PCr/ATP], primary outcome) and function (rest and dobutamine s","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T18:35:42.567Z","creation":"2026-07-09T11:15:10.496Z"},"accession":"S-EPMC12928817","cross_references":{"pubmed":["41410037"],"doi":["10.1161/CIRCULATIONAHA.125.074041"]}}